Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
Myriam El Gaaloul(Medicines for Malaria Venture), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Jean Louis Ndiaye(Université de Thiès), Hanu Ramachandruni(Medicines for Malaria Venture), Timothy N. C. Wells(University of Bern), Jane Achan(Malaria Consortium), Céline Audibert(Medicines for Malaria Venture), Bénédicte Buffet(Medicines for Malaria Venture), André-Marie Tchouatieu(Medicines for Malaria Venture), Cristina Donini(Medicines for Malaria Venture), Brice Campo(Medicines for Malaria Venture), Hellen C. Barsosio(Liverpool School of Tropical Medicine), Kassoum Kayentao(University of Bamako)
Cited by 13
Related Papers
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345
Cloning and Characterization of a Specific Receptor for the Novel CC Chemokine MIP-3α from Lung Dendritic Cells
|The Journal of Experimental Medicine|1997|289